Showing 1 posts of 1 posts found.
Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …
Hot-tub therapy tested as potential treatment for peripheral artery disease
Raimond takes helm at Nuclera
Most advanced breast cancer patients treated in community settings, Phesi study finds
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Bramacare opens supported-living facility for eating disorder recovery